Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature

Wiley - Tập 80 Số 4 - Trang 355-367 - 2002
Sohan Singh Hayreh1, Bridget Zimmerman2, Randy H. Kardon3
1Department of Ophthalmology and Visual Sciences, College of Medicine, University of Iowa, Iowa 52242, USA.
2Department of Biostatistics, College of Public Health, University of Iowa, Iowa, USA
3Department of Ophthalmology & Visual Sciences, College of Medicine, University of Iowa, Iowa, USA

Tóm tắt

ABSTRACT.Objectives:  (1) To report the incidence and extent of visual improvement achieved by high‐dose systemic corticosteroid treatment in eyes with visual loss due to giant‐cell arteritis (GCA). (2) To understand the cause of the discrepancies between visual improvement revealed by routine visual acuity (VA) and by the central visual field in kinetic perimetry. (3) To review critically the contradictory literature on the effectiveness of corticosteroid therapy on visual recovery in GCA and to attempt to reconcile differences in the reported results.Methods:  Clinical data were collected systematically on 84 consecutive patients (114 eyes) with visual loss, all of whom had GCA confirmed by temporal artery biopsy and treated by us with high‐dose systemic corticosteroid therapy. The patients were treated between 1974 and 1999 and data were compiled retrospectively. All patients underwent a detailed visual and ophthalmic evaluation at the initial visit and at every follow‐up. This included visual field testing (with a Goldmann perimeter). All were treated with systemic corticosteroid therapy (intravenous followed by oral in 41 patients and oral only in 43 patients).Results:  Visual loss was due to anterior ischaemic optic neuropathy (91%), central retinal artery occlusion (10.5%), cilioretinal artery occlusion (10%), and/or posterior ischaemic optic neuropathy (4%), either alone or in different combinations. Improvement in both VA (≥ 2 lines) and central visual field was found in only five (4%) eyes of five patients (three treated with intravenous and two with oral steroid therapy). Improvement in VA ≥ 2 lines but not in the central visual field was found in seven eyes (in six patients). Visual improvement was seen in 7% of 41 patients treated initially with intravenous steroids versus 5% (p = 0.672) of 43 patients treated with oral steroids only. Comparison of patients with visual improvement in both VA and fields versus those with no improvement suggested a shorter interval (p = 0.065) between onset of visual loss and start of therapy in the improved patients.Conclusions: In our study, only 4% of eyes with visual loss due to GCA improved, as judged by improvement in both VA and central visual field (by kinetic perimetry and Amsler grid). The data also suggest that there is a better (p = 0.065) chance of visual improvement with early diagnosis and immediate start of steroid therapy. Improvement in VA without associated improvement in the central visual field or Amsler grid may simply represent a learned ability to fixate eccentrically with more effective use of remaining vision: this factor could help explain a number of reported cases in the literature of improved VA after steroid treatment for GCA. To prevent further visual loss in either eye and for management of systemic manifestations of GCA, all patients must be treated on a long‐term basis with adequate amounts of systemic corticosteroids.

Từ khóa


Tài liệu tham khảo

10.1016/S0161-6420(93)31608-8

10.1111/j.0954-6820.1981.tb11604.x

Bengtsson B‐A, 1982, Giant cell arteritis, Acta Med Scand (Suppl. ), 658, 1

10.1136/bjo.40.7.430

10.1016/0002-9394(56)90527-X

10.1016/S0161-6420(92)31777-4

10.1016/0002-9343(92)90793-B

Cohen DN, 1973, Temporal arteritis: Improvement in visual prognosis and management with repeat biopsies, Trans Am Acad Ophthalmol Otolaryngol, 77, 74

Cullen JF, 1963, Occult temporal arteritis, Trans Ophthalmol Soc UK, 83, 725

10.1136/bjo.75.7.432

10.1016/0002-9394(65)90936-0

10.1136/bmj.282.6260.269

10.1212/WNL.56.7.830

10.1136/bjo.46.4.212

10.1136/bjo.53.11.721

10.1136/bjo.58.12.964

10.1007/978-3-642-65957-7

10.1016/S0014-4835(05)80121-6

10.1016/S0161-6420(99)10101-5

10.1016/S0140-6736(00)02210-8

10.1016/S1350-9462(01)00004-0

10.1136/bjo.56.10.719

10.1001/archopht.1982.01030040459019

10.1016/S0002-9394(00)00384-6

10.1016/S0002-9394(14)70123-0

10.1016/S0002-9394(14)70902-X

10.1016/S0002-9394(99)80192-5

10.1016/S0002-9394(99)80193-7

10.1016/S0002-9394(14)70067-4

10.1016/0002-9394(70)91859-3

10.1001/archopht.1976.03910030306011

10.1016/S0140-6736(00)86182-6

10.1212/WNL.53.1.177

Kearns TP, 1973, Temporal arteritis: Improvement in visual prognosis and management with repeat biopsies. (Discussion), Trans Am Acad Ophthalmol Otolaryngol, 77, 84

Kearns TP, 1975, The Eye and Systemic Disease, 105

10.1136/bjo.83.7.796

10.1001/archinte.145.12.2252

10.1016/S0161-6420(94)31102-X

MacMichael IM, 1972, The Optic Nerve., 108

10.1016/S0161-6420(92)32009-3

10.1136/bjo.51.8.505

10.1136/bjo.62.9.591

Meadows SP, 1954, Temporal arteritis and loss of vision, Trans Ophthalmol Soc UK, 74, 13

10.1016/S0140-6736(78)90126-5

Norn MS, 1966, Arteritis temporalis, Ugeskr Laeger, 128, 532

10.1136/bjo.43.4.204

10.1016/S0002-9394(98)00437-1

Postel EA, 1993, Recovery of vision in a 47‐year‐old man with fulminant giant cell arteritis, J Clin Neuroophthalmol, 13, 262

10.1016/S0161-6420(99)90165-3

10.1016/0002-9343(86)90066-5

Russell RWR, 1959, Giant cell arteritis, Q J Med, 28, 471

Schneider HA, 1971, The visual prognosis in temporal arteritis, Ann Ophthalmol, 3, 1215

10.1097/00132578-200107000-00003

10.1001/archopht.1960.01840010864006

10.1111/j.1755-3768.1994.tb04696.x

10.1016/S0140-6736(53)91590-6

Thông tin
Thông tin xuất bản

Wiley

Tập 80 Số 4

355-367

Thông tin tác giả